Prions, characterized by self-propagating protease-resistant prion protein (PrP) conformations, are agents causing prion disease. Recent studies generated several such self-propagating protease-resistant recombinant PrP (rPrP-res) conformers. While some cause prion disease, others fail to induce any pathology. Here we showed that although distinctly different, the pathogenic and non-pathogenic rPrP-res conformers were similarly recognized by a group of conformational antibodies against prions and shared a similar guanidine hydrochloride denaturation profile, suggesting a similar overall architecture. Interestingly, two independently generated non-pathogenic rPrP-res were almost identical, indicating that the particular rPrP-res resulted from cofactor-guided PrP misfolding, rather than stochastic PrP aggregation. Consistent with the notion that cofactors influence rPrP-res conformation, the propagation of all rPrP-res formed with phosphatidylglycerol/RNA was cofactor-dependent, which is different from rPrP-res generated with a single cofactor, phosphatidylethanolamine. Unexpectedly, despite the dramatic difference in disease-causing capability, RT-QuIC assays detected large increases in seeding activity in both pathogenic and non-pathogenic rPrP-res inoculated mice, indicating that the non-pathogenic rPrP-res is not completely inert in vivo. Together, our study supported a role of cofactors in guiding PrP misfolding, indicated that relatively small structural features determine rPrP-res' pathogenicity, and revealed that the in vivo seeding ability of rPrP-res does not necessarily result in pathogenicity.
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Introduction
Transmissible spongiform encephalopathies (TSEs), also known as prion diseases, are a group of fatal neurodegenerative disorders affecting both humans and other mammals [1] . A central pathogenic event in prion disease is conformational conversion of the host-encoded prion protein (PrP C ), a normal, protease-sensitive, cell-surface localized glycoprotein, to a misfolded and protease-resistant pathogenic conformer, PrP Sc [1] [2] [3] [4] [5] . As an unorthodox infectious agent, PrP Sc replicates itself by imprinting its distinctive infectious conformation on host PrP C molecules [6] . The molecular mechanisms underlying the in vivo PrP C -to-PrP Sc conversion are largely unknown. Recent in vitro studies have revealed that bacterially expressed recombinant PrP (rPrP) can be converted into pathogenic conformations in a test tube and those pathogenic forms cause bona fide prion disease in animals [7] [8] [9] [10] [11] [12] [13] . Even though some in vitro rPrP conversions in the absence of any additives have produced prion infectivity [11] [12] [13] , generation of rPrP pathogenic conformers with a proper, i.e. scrapie-like, proteinase K (PK)-resistant pattern and a high titer of prion infectivity have so far been achieved only in the presence of cofactors [7] [8] [9] [10] . The serial protein misfolding cyclic amplification (sPMCA) is one of the methods commonly used to study prion conversion in vitro [14, 15] . During sPMCA, a mixture of PrP C -containing normal brain homogenate plus a small amount of PrP Sc -containing diseased brain homogenate is subject to successive cycles of sonication and incubation, allowing simultaneous propagation of the PrP Sc conformers and prion infectivity [16] . The enormous amplification power makes sPMCA a sensitive tool for detecting minute amounts of PrP Sc , and this methodology has been successfully used for the diagnosis of prion disease [17, 18] .
The sPMCA can also be performed without any seed, allowing de novo generation of PrP Sc . Using the latter approach, we have shown that, in the presence of total RNA isolated from mouse liver plus synthetic phospholipid POPG (1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1 0 -rac-glycerol), recombinant murine prion protein (rPrP) purified from E. coli can be converted into the highly infectious and PK-resistant conformer rPrP-res RNA [7, 19] , which causes prion disease in wild-type animals and has the same pathogenic properties as naturally occurring prions [8] . A similar conversion system, containing rPrP, total mouse liver RNA, and POPG, was used at the NIH Rocky Mountain Laboratory to produce an rPrP-res conformer (rPrP-res NIH ) de novo [20] . Interestingly, despite its ability to propagate indefinitely by sPMCA, rPrP-res NIH does not cause disease in vivo [20] .
In sPMCA reactions seeded by native murine prions or rPrP-res RNA , phosphatidylethanolamine (PE) was found to allow rPrP conversion into the PK-resistant and highly pathogenic conformer rPrP-res PE as the only cofactor [10] . Omitting the PE cofactor resulted in either the halting of rPrP-res PE propagation or the generation of a cofactor-independent, "protein-only", PK-resistant conformer rPrP-res protein-only that failed to induce any pathology in mice [21] . The non-pathogenic rPrP-res protein-only has a smaller PK-resistant core than rPrP-res PE , but nonetheless can be propagated indefinitely by sPMCA [21] . The fact that the non-pathogenic rPrPres protein-only could be propagated in the absence of any cofactor raised a series of interesting questions. Is the lack of infectivity in certain non-pathogenic rPrP-res conformers due to the absence of cofactors? Are cofactors required for the propagation of other non-pathogenic rPrP-res conformers? Do all non-pathogenic rPrP-res conformers share the same structure? And how significant is the difference between the structures of the non-pathogenic and pathogenic rPrP-res conformers?
Here we performed detailed comparisons between the highly pathogenic rPrP-res RNA and two independently formed, non-pathogenic rPrP-res conformers in terms of their propagation, PK-resistance patterns, conformational differences, capability of infecting cultured cells, and seeding of rPrP amyloid fibril growth. Our results provided novel insights into the relationship among cofactors, self-propagating conformations, and bona fide prion infectivity.
Results

De novo formed rPrP-res RNA-low does not contain detectable in vivo pathogenicity
We previously reported that in the presence of total mouse liver RNA and synthetic POPG, purified and fully folded rPrP can be converted into highly pathogenic recombinant prion (rPrP-res RNA ) in an unseeded sPMCA reaction [7] . Using the same protocol, we found that another rPrP-res form, rPrP-res RNA-low , could also be generated de novo (S1 Fig). The rPrPres RNA-low has a smaller PK-resistant core (about 15 kDa, vs.~16 kDa for rPrP-res RNA ). Similar to the pathogenic rPrP-res RNA , rPrP-res RNA-low can propagate indefinitely by sPMCA ( Fig 1A) .
To determine whether rPrP-res RNA-low is pathogenic in vivo, we intracerebrally inoculated wild-type C57BL/6 mice with rPrP-res RNA or rPrP-res RNA-low . Consistent with our previous report [7] , mice inoculated with rPrP-res RNA developed prion disease after a relatively synchronized incubation period and presented histopathological changes in the brain typical of prion disease (Table 1) . In animals inoculated with rPrP-res RNA-low , multiple animal bioassays (including secondary transmission in wild-type C57BL/6 mice or intracerebral inoculation in Tga20 transgenic mice that overexpress wild-type PrP C (Table 1) ) failed to show any signs of prion disease, or any pathology. Brain homogenates from rPrP-res RNA-low mice sacrificed at 477-583 dpi (days post injection) were subjected to PK digestion and no PK-resistant PrP was detected in those mice (Fig 1B) . The lack of pathology was also confirmed by histopathological analyses (S2-S5 Figs). Compared to the traditional rodent bioassay, the Elispot-based cultured-cell prion infection assay is a sensitive, more rapid and economical assay [22, 23] . Because of the restrictive sensitivity of cultured cells to prion strains, we chose CAD5 cells, which are known to be susceptible to a broad spectrum of murine prion strains [22, 23] . When naïve CAD5 cells were infected with either rPrP-res RNA or rPrP-res RNA-low , the Elispot data matched very well with traditional animal bioassay results [8] , showing a significant amount of prion infectivity from rPrP-res RNA , but none from rPrP-res RNA-low ( Fig 1C) .
Lysates of the CAD5 cells used in the Elispot assay were further verified by classic PK digestion and western blots, confirming that rPrP-res RNA efficiently converted endogenous PrP Together, these results confirmed that the self-propagating rPrP-res RNA-low does not cause any pathology in vivo, nor does it contain any detectable prion infectivity in cell culture assay. Moreover, these data suggest that the co-existence of a self-propagating PK-resistant rPrP conformation and cofactors does not automatically produce prion infectivity.
Cofactors are required for propagating both rPrP-res RNA and rPrPres
RNA-low
Since the non-pathogenic rPrP-res protein-only is able to replicate without any cofactor [21] , we tested whether the propagation of rPrP-res RNA-low was cofactor-dependent. The sPMCA was carried out either with substrate lacking any cofactor and containing only rPrP or with the complete substrate, i.e., rPrP plus cofactors. In the presence of cofactors, both pathogenic rPrP-res RNA and non-pathogenic rPrP-res RNA-low were propagated efficiently, but in the absence of cofactors, neither of the conformers sustained their propagation (Fig 2A) . The requirement of cofactors for rPrP-res RNA-low propagation suggests that even though rPrPres RNA-low shares with rPrP-res protein-only the properties of being non-pathogenic and a smaller PK-resistant core, it is different from the cofactor-independent rPrP-res protein-only .
Since the lack of PK-resistant PrP does not always correlate with loss of prion infectivity [24] , we determined whether the failure of rPrP conversion correlated with a loss of infectivity by the Elispot infection assay. The rPrP-res RNA was used to seed sPMCA reactions with either complete substrate or substrate lacking the cofactor for 6 rounds to ensure that no residual infectivity was carried over from the infectious rPrP-res RNA seed. As expected, the rPrP-res conformer was only generated in the presence of cofactors, but not in the cofactor-free reactions ( Fig 2B) . The 6th-round sPMCA products were used to infect naïve CAD5 cells, and the Elispot assay revealed that the prion infectivity had been propagated along with rPrP-res RNA in regular sPMCA, but no prion infectivity was detected in sPMCA performed in the absence of cofactors ( Fig 2C and S7 Fig) . These results support an intimate association between the selfpropagating rPrP-res conformations and prion infectivity.
Biochemical and morphological properties of rPrP-res RNA and rPrPres RNA-low Although rPrP-res RNA and rPrP-res RNA-low were propagated under exactly the same conditions-i.e., using the same batch of rPrP, the same batch of cofactors, and the same sPMCA parameters-these two rPrP-res conformers differed drastically in their biological activities. This difference led us to ask whether these two conformers differed in any of their other properties besides the obvious size difference in their PK-resistant cores. We found that both rPrPres RNA and rPrP-res RNA-low appeared in the pellet fraction after ultracentrifugation (Fig 3A) , suggesting that both were aggregated. Analysis of these aggregates by atomic force microscopy (AFM) revealed the presence of relatively short fibrillar structures that clumped together forming large aggregates ( Fig 3B, R and R-low), and became more apparent when large clumps were partially dispersed by sonication ( Fig 3B, R (sonicated) ). No obvious morphological differences could be detected by AFM between rPrP-res RNA and rPrP-res RNA-low aggregates. It should be noted that fibrillar clumps were accompanied by nonfibrillar particles of varied morphologies (in some fields imaged by AFM only the latter structures were seen). However, similar particles were also present in control sPMCA samples containing cofactors in the absence of rPrP (Fig 3B, control) , making it difficult to conclude whether such nonfibrillar particles correspond to rPrP-containing structures or those formed by cofactors only. Western blots probed with anti-PrP antibodies, i.e., monoclonal 6D11 (recognizing an epitope of 93-109 of PrP) and polyclonal M20 (recognizing PrP90-230), showed that the PKresistant core of rPrP-res RNA-low was a C-terminal fragment similar to that of rPrP-res RNA ( Fig   4A) . Notably, the size difference between the cores remained relatively constant following digestions with increasing amounts of PK (Fig 4B, POM1 ), indicating that both rPrP-res forms have relatively stable PK-resistant cores. The monoclonal 3F10 antibody, recognizing an epitope encompassing residues 137-151 of PrP [25] , detected more PK-resistant fragments on the same blot (Fig 4B, 3F10 ). The banding patterns were consistent and distinct for rPrP-res RNA and rPrP-res RNA-low , particularly the stronger small bands of rPrP-res RNA-low at the forefront of the gel (Fig 4B, 3F10 , arrow), confirming the structural difference between those two rPrPres conformers.
To further probe the conformational differences between rPrP-res RNA and rPrP-res RNA-low ,
we performed an immunoprecipitation assay with a panel of four conformational antibodies that were raised to specifically capture PrP Sc molecules [26, 27] . Interestingly, none of the . (A) Two hundred microliters of sPMCA products of rPrP-res RNA (R) and rPrP-res RNA-low (R-low) were centrifuged at 100,000 x g at 4˚C for 1 h. The supernatant was collected and the pellet was resuspended in 200 μL of PMCA buffer. For the total (T), supernatant (S), and pellet (P) fractions, 1 μL of each fraction was loaded onto SDS-PAGE; for PK digested samples, 10 μL of S or P was subjected to PK digestion followed by SDS-PAGE and western blotting. (B) Representative atomic force microscopy images of different rPrP-res aggregates. Control sample contains cofactors only in the absence of rPrP. The sample was processed in identical way as those containing rPrP. Upper panels are images of Control, rPrP-res RNA-low (R-low), rPrP-res RNA (R) and sonicated rPrP-res RNA (R (Sonicated)) at lower magnification. Bottom panels are images of rPrP-res RNA-low (R-low), rPrP-res RNA (R) and sonicated rPrP-res RNA (R (Sonicated)) at higher magnification. Bars at each panel represent 400 nm. antibodies was able to unambiguously differentiate rPrP-res RNA from rPrP-res RNA-low ( Fig   5A) , suggesting that despite the obvious difference in the size of their PK-resistant cores, the pathogenic and non-pathogenic rPrP-res forms share a similar overall architecture. This conclusion was further supported by the guanidine hydrochloride (GdnHCl) denaturation assay ( Fig 5B) . In this assay, increased concentrations of GdnHCl gradually solubilize aggregated rPrP-res, allowing a differentiation of different prion strains [28] . Notably, when rPrP-res RNA and rPrP-res RNA-low were exposed to increased concentrations of GdnHCl, the [GdnHCl] 1/2 for the two were 2.22 ± 0.13 and 2.15 ± 0.35, respectively. Moreover, the curves of insoluble rPrP were very similar and no statistical difference could be detected at any GdnHCl concentration ( Fig 5B) . Thus, both the conformational antibody binding and GdnHCl denaturation assay suggest that rPrP-res RNA from rPrP-res RNA-low share a similar overall architecture.
The rPrP-res NIH shares the same biochemical properties with rPrPres
Because the pathogenic rPrP-res RNA and non-pathogenic rPrP-res RNA-low were generated in the same lab, we expanded our comparison to another non-pathogenic conformer, rPrPres NIH , which was generated de novo independently at the NIH Rocky Mountain Laboratory [20] . The banding patterns of rPrP-res RNA-low and rPrP-res NIH detected by the POM1 and 3F10 antibodies were almost identical, highlighted by the stronger small bands detected by the 3F10 antibody (Fig 6A, arrow) . The sPMCA results showed that rPrP-res NIH was able to propagate in a separate laboratory under the same conditions used to generate rPrP-res RNA and rPrP-res RNA-low ( Fig 6B) . More importantly, the propagation of rPrP-res NIH also depended on the presence of the cofactor molecules (Fig 6C) . The Elispot assay using CAD5 cells confirmed that both rPrP-res RNA-low and rPrP-res NIH lacked the capability of converting endogenous Fig 6D and S1 Appendix) . Collectively, our results revealed that despite being generated de novo in two independent laboratories, the non-pathogenic rPrP-res RNA-low and rPrP-res NIH resemble each other, suggesting that they represent the same non-pathogenic, self-propagating rPrP-res structure. Thus, the de novo rPrP-res formation is likely via a distinct PrP misfolding pathway guided by POPG/RNA cofactors.
Both pathogenic and non-pathogenic rPrP-res conformers seed rPrP amyloid fibrils growth
One characteristic of native prions is their ability to seed rPrP amyloid fibril formation [29] [30] [31] . Using the semi-denaturing rPrP amyloid fibril formation assay that monitors fibril growth with Thioflavin T (ThT) fluorescence [32] , we found that all three rPrP-res conformers-pathogenic rPrP-res RNA , non-pathogenic rPrP-res RNA-low , and non-pathogenic rPrP-res NIH -seeded amyloid fibril formation (Fig 7) . The lag phases of reactions seeded by rPrP-res RNA-low and rPrP-res NIH were similar, in both cases, significantly shorter than that of rPrP-res RNAseeded reactions (Fig 7A) . Furthermore, the lag phases of all rPrP-res-seeded reactions were significantly longer than reactions seeded by preformed rPrP amyloid fibrils. The amyloid fibrils seeded by all three rPrP-res conformers were morphologically indistinguishable from each other or from those seeded by the preformed rPrP amyloid fibrils (Fig 7B) . In addition, the amyloid fibrils seeded by either pathogenic or non-pathogenic rPrP-res conformers showed no infectivity in the Elispot cell infection assay (S9 Fig) .
Detecting in vitro and in vivo seeding activity of rPrP-res RNA and rPrPres RNA-low by RT-QuIC
The real-time quaking induced conversion assay (RT-QuIC) is a newly developed prion seeding assay that is also based on the ability of prions to seed rPrP amyloid fibril growth. The RT-QuIC, using a non-denaturing, near-neutral pH reaction system different than the semi- . Two-way ANOVA analyses followed by Tukey's multiple comparisons test in GraphPad Prism revealed that there is no significant difference between either rPrP-res RNA (R) and rPrP-res NIH (NIH) or rPrP-res RNA-low (R-low) and rPrP-res NIH (NIH).
https://doi.org/10.1371/journal.ppat.1006491.g006
Self-propagating recombinant prions and pathogenicity denaturation system for rPrP amyloid fibril growth used in the above experiments, is highly sensitive and has been successfully used to diagnose prion disease in humans and animals [31, [33] [34] [35] . Using this assay, we compared the in vitro and in vivo seeding activity of the pathogenic rPrP-res RNA and non-pathogenic rPrP-res RNA-low .
Both rPrP-res RNA and rPrP-res RNA-low were able to seed rPrP amyloid fibril growth in the RT-QuIC assay (Fig 8A) . Since prion strain differences can be observed in the immunoblot banding profile of PK-digested RT-QuIC products [36] , we subjected the rPrP-res RNA -or rPrP-res RNA-low -seeded RT-QuIC products to PK-digestion and western blot with the R20 antibody (recognizing residue 218-231 of hamster PrP). The PK-resistant banding patterns were almost identical except for a small PK-resistant band (Fig 8B, Left panel, indicated by an arrow), which is much more prominent in samples seeded by the pathogenic rPrP-res RNA . This result is consistent with the notion that rPrP-res RNA and rPrP-res RNA-low share a similar overall architecture, but have distinct small structural features. https://doi.org/10.1371/journal.ppat.1006491.g007
Self-propagating recombinant prions and pathogenicity
Brain homogenates were prepared from three rPrP-res RNA -inoculated mice at terminal stage (rPrP-res RNA -BH) and three rPrP-res RNA-low -inoculated mice ( Table 1) . As expected, prion seeding activity was detected in rPrP-res RNA -BH (Fig 8C, upper panel) . Surprisingly, positive RT-QuIC results were also obtained with brain homogenates prepared from all three mice inoculated with non-pathogenic rPrP-res RNA-low (rPrP-res RNA-low -BH), which were without any signs of neurological dysfunction (Fig 8C, lower panel) . To quantitate the total seeding activity, we performed end-point RT-QuIC quantitation [37] of the original inocula and the inoculated brain homogenates (Fig 8D) . The log SD 50 of the rPrP-res RNA-low inoculum was 4.95 /μl, which gave a total SD 50 of 10 6.25 in the 20 μl inoculum (volume used to inject one mouse). Assuming that the total weight of a mouse brain is around 500 mg, the total SD 50 in https://doi.org/10.1371/journal.ppat.1006491.g008
Self-propagating recombinant prions and pathogenicity the brain of Br354 mouse was around 10 8.4 . The more than two orders of magnitude increase suggests that some amplification of the seeding activity occurred in the non-pathogenic rPrPres RNA-low -inoculated brain. Consistent with this interpretation, seeding activity was detected in each of 5 mice receiving secondary transmission from a mouse (Br355) that was inoculated with the non-pathogenic rPrP-res RNA-low (S10 Fig). Quantitative RT-QuIC comparisons of the Br355-derived inoculum and the brains of the second passage mice indicated~1,700-fold increases in seeding activity in each case. The brain homogenate seeded RT-QuIC products were also subject to PK-digestion and western blot analysis (Fig 8B, right panel) . All of the PK-resistant bands detected in the RT-QuIC products seeded with rPrP-res RNA were detected in the RT-QuIC products seeded by rPrP-res RNA -BH (Fig 8B) , indicating a faithful in vivo propagation of the rPrP-res RNA conformation. Although the non-pathogenic rPrP-res RNA-low -BH seeded RT-QuIC products also retained most of the PK-resistant bands, extra PK-resistant bands were also detected (Fig 8B, right panel, asterisk represents an example), which may reflect an adaptation of the non-pathogenic rPrP-res RNA-low to the in vivo environment.
Together, these findings provided further support for the overall similarity between two distinct rPrP-res conformers. More importantly, the end-point analysis provided the first evidence that despite the drastic difference in pathogenicity, both rPrP-res conformers are active in vivo.
Discussion
Our study revealed that although rPrP-res RNA-low appears active and leads to the replication of prion seeding activity in vivo, it does not automatically result in pathogenic changes or the development of prion disease, at least for two consecutive passages in wild-type mice. The pathogenic and non-pathogenic rPrP-res conformers show many similarities in their overall architecture, suggesting that relatively small structural differences determine distinct biological properties of these rPrP-res aggregates. Moreover, our results support a critical role of cofactor in guiding the de novo rPrP-res formation, and suggest that different cofactors guide PrP misfolding in distinct manners, resulting in different rPrP-res conformers. An interesting finding of this study is the ability of rPrP-res RNA-low to cause the replication of seeding activity in vivo. This finding is reminiscent of previous reports that GSS patients' brain homogenates containing only PrP amyloid fibrils, brain homogenates from diseased transgenic mice overexpressing P101L PrP, or synthetically generated rPrP amyloid fibrils are able to seed PrP amyloid plaque formation, but completely fail to cause any pathological changes of prion disease in P101L knock-in mice [38] [39] [40] . However, it has to be noted that we did not observe any PrP amyloid plaques in rPrP-res RNA-low inoculated mouse brains.
Together with the facts that wild-type mice were used in our analyses and that amyloid fibrils were likely only a part of rPrP-res (fibrils were only detected in certain fields with highly concentrated, PK-digested rPrP-res preparations), the rPrP-res RNA-low likely propagates in vivo in a manner different from amyloid fibril seeding in P101L knock-in mice. Nevertheless, both lines of studies support that the in vivo PrP seeding does not necessarily lead to disease pathology. The most likely reason for the difference in pathogenicity is the structural difference between rPrP-res RNA and rPrP-res RNA-low . Interestingly, our results revealed a similar architecture (and thus likely similar overall folding motif) of the pathogenic rPrP-res RNA and nonpathogenic rPrP-res RNA-low , which likely resulted from the strong influence of RNA and POPG cofactors on rPrP structure [41] [42] [43] that guides rPrP conversion. It appears that relatively minor structural differences between rPrP-res conformers are sufficient to result in large differences in in vivo pathogenicity. Understanding the nature of these structural differences requires studies employing higher resolution biophysical methods, and such future studies are of fundamental importance to understanding the molecular basis for prion infectivity.
The role of cofactor molecules in generating infectious prions is supported by many in vitro conversion studies [7, 10, 21, [44] [45] [46] , but the mechanisms are yet to be established. The highly pathogenic rPrP-res RNA and rPrP-res PE were formed with two different sets of cofactors, RNA +POPG [7] or PE only [10] , respectively, and have displayed distinct prion strain properties in mice [21] . When PE was omitted from the sPMCA reaction, the propagation of rPrP-res PE either stopped or led to the emergence of rPrP-res protein-only , which has a smaller PK-resistant core and no detectable in vivo pathogenicity [21] . Adding PE back to rPrP-res protein-only -seeded sPMCA reactions did not restore the rPrP-res PE conformer [21] . In this study, no "protein-only", self-propagating, rPrP-res conformer was formed in the absence of cofactors in either rPrP-res RNA -or rPrP-res RNA-low -seeded sPMCA reactions, which is different from those seeded by rPrP-res PE [21] . Many factors may account for this difference, but the difference between the two sets of cofactors is likely to be the key. Full-length rPrP has a high isoelectric point (pI > 9) and binds to negatively charged RNA and POPG [41, 42] . We and other groups have shown that the binding of rPrP to anionic lipids or RNA results in significant rPrP conformational changes [41] [42] [43] 47] . PE, on the other hand, is a neutral phospholipid that has little or no in vitro interaction with rPrP [47] . The sonication in sPMCA may foster a unique rPrP-PE interaction leading to the formation of PE-dependent rPrP-res PE . Thus, both rPrP-res PE and rPrP-res RNA can be propagated in sPMCA, but likely through different pathways, which is in agreement with their different strain properties in vivo [21] . Consistent with the idea that different cofactors used in sPMCA may lead to different rPrP conformations, the non-pathogenic rPrP-res forms derived from two sPMCA reactions, rPrP-res RNA-low and rPrP-res protein-only , have drastic differences in cofactor dependence in their propagation, which strongly indicates a difference in their structures. Even though native prions are generally not present with fibrillar structure in vivo, diseased brain homogenates do have the ability to seed rPrP amyloid fiber formation [29] [30] [31] 48] , and this property has been successfully developed into an ultrasensitive diagnostic tool [33] . Our data showed that, akin to brain-derived prions, all three cofactor-dependent rPrP-res conformers studied are able to seed rPrP amyloid fibril growth, supporting the structural similarity among those conformers. The non-pathogenic forms (i.e. rPrP-res RNA-low and rPrP-res NIH ) have apparently stronger seeding capacity than the pathogenic rPrP-res RNA in the amyloid fibril formation assay, which may reflect the fact that the non-pathogenic rPrP-res RNA-low maintains more seeding competent conformation in the presence of 2M GdnHCl, a semidenaturing buffer system used for growing rPrP amyloid fibrils [32] . However, using the nondenaturing conditions of RT-QuIC, the seeding activity of the non-pathogenic form was about a log lower than the pathogenic form. This again suggests differences in the conformation and seeding capabilities of these two conformers.
In summary, our current study provides evidence that (i) cofactors are able to guide rPrP misfolding to result in different rPrP-res conformers, (ii) unique structural features of the rPrP-res determine the pathogenicity, and (iii) the in vivo rPrP-res seeding activity is not necessarily equal to disease pathogenicity. These novel insights help to elucidate the molecular basis for prion infectivity.
Materials and methods
Generation of rPrP-res
Recombinant murine PrP 23-230 purification and sPMCA experiments were performed as previously described [7, 19, 45, 49] . For seeded sPMCA, 10 μL of rPrP-res RNA seed was added to the substrate and the mixture was subjected to 1 round of PMCA. After each round, 10 μL of the PMCA product was transferred to a new tube containing 90 μL of substrate for another round. For unseeded PMCA, the same protocol was followed except that 10 μL of PBS instead of rPrP-res RNA was added to the first tube of substrate. For the cofactor-free sPMCA, mouse liver total RNA and synthetic phospholipid POPG were omitted during substrate preparation.
To detect the generation of rPrP-res, 10 μL of PMCA product was incubated with 10 μL PK (100 μg/mL unless stated otherwise) for 30 min at 37˚C followed by the addition of 2 mM PMSF. The PK-digested samples were subjected to SDS-PAGE and western blotting. All the PK-resistant PrP fragments were detected using POM1 primary anti-PrP antibody [50] unless stated otherwise.
The enzyme-linked immunospot (Elispot) cell infection assay
The Elispot cell infection assay was adapted from previous studies [22, 23] with minor adjustments. Briefly, 200 μL of PMCA products at round 6 were collected and centrifuged at 100,000 x g for 1 h at 4˚C. The pellets were then washed twice, with centrifugation at 100,000 x g for 1 h at 4˚C after each wash. After the final wash, the pellets were resuspended in 200 μL of CAD5 growth media (OPTI-MEM, 5% BGS, and 1% penicillin and streptomycin) and sonicated for 30 sec with 50% output using a Misonic Sonicator (XL2020). Then each sample was serially diluted 10, 100, and 1,000 times, and 60 μL of undiluted and diluted samples were used to infect CAD5 cells. After two 1:10 splits, 20,000 CAD5 cells/well were transferred to the Millipore 96-well Elispot plates (MSIPN4W) and subjected to the Elispot assay. The images were taken by S6 Micro Analyzer (CTL Analyzers, LLC) and processed by the ImmunoSpot software (CTL Analyzers, LLC). The graph was generated using GraphPad Prism (GraphPad Software, Inc.). To validate the Elispot data, the remaining infected cells were lysed and subjected to PK digestion (100 μg/mL PK, 37˚C, 30 min) and SDS-PAGE. The PK-resistant PrP fragments were detected by western blots using POM1 anti-PrP antibody.
Mouse bioassays
The mouse bioassays were performed as previously described [7, 19, 45, 49] . In brief, 20 μL of purified rPrP-res was inoculated into a mouse intracerebrally. Second-round transmission, animal monitoring, biochemical analyses, and histopathological analyses were performed as previously described [7, 19, 45, 49] .
Ethics statement
This study was carried out in accordance with the recommendations in the Guide for the Immunoprecipitation with anti-PrP Sc conformational antibodies Protein-G DynalBeads (100 μL; Life Technologies) were washed twice with 250 μL of coating buffer (0.1% BSA in PBS), incubated in 250 μL of coating buffer at 4˚C overnight, and then resuspended in 300 μL of coating buffer for use. The rPrP-res-seeded PMCA products containing 100 ng of PrP were incubated with no antibody or with 2.5 μg of conformational antiPrP Sc antibodies in 250 μL of incubation buffer (10 mM Tris, 150 mM NaCl, 0.28% Triton X-100, pH 7.5) at 4˚C overnight, then mixed with 30 μL of resuspended coated beads and incubated at room temperature for 4 h, followed by washing 3 times with 100 μL of incubation buffer. The beads were then resuspended in 20 μL of SDS-PAGE sample buffer, boiled for 10 min, and subjected to SDS-PAGE and western blotting for detection of PrP using the anti-PrP M-20 polyclonal antibody.
Conformational stability assay
The conformational stability assay was performed as previously described [28] . Briefly, aliquot of rPrP-res RNA , rPrP-res RNA-low or rPrP-res NIH was mixed with an equal volume of GdnHCl solutions to reach final concentrations of 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, and 4.0 M and kept at 37˚C for 1 h, followed by centrifugation at 20,000 x g for 1 h at 22˚C. Supernatants were removed and pellets were resuspended in SDS-PAGE sample buffer and subjected to SDS-PAGE and western blotting for detecting PrP using the anti-PrP POM1 antibody. Western blotting images were obtained with Fujifilm LAS-4000 imaging system and banding intensity was quantified with ImageJ. The denaturation curves for each rPrP-res conformer were generated by fitting the insoluble PrP (%) as a function of GdnHCl concentrations using a Sigmoidal, 4 parameter logistic equation in GraphPad Prism.
Amyloid fibril formation assay
Amyloid fibril formation was performed as previously described [51] . For unseeded growth, 0.5 mg/mL of rPrP was incubated in 2 M guanidine hydrochloride (GdnHCl), 100 mM potassium phosphate buffer, pH 6.5, and 20 μM Thioflavin T (ThT). The reaction volume was 200 μL per well in 96-well plates (Corning, Lot No. 065514030). In seeded reactions, 1 μL of preformed mouse rPrP fibrils (0.5 mg/mL) or 5 μL of treated rPrP-res was added to each well. The plate was incubated at 37˚C with continuous shaking on a microplate reader (SYNERGY2, BioTek). The fibril kinetics was monitored by measuring ThT fluorescence intensity every 15 min using 440-nm excitation and 480-nm emission. The amyloid-formation kinetics was generated using GraphPad Prism (GraphPad Software, Inc.). The lag time was determined when the ThT fluorescence reached threefold above the baseline [52] .
The sPMCA products of each rPrP-res conformer were digested with Benzonase and PK and purified as previously described [20] to seed amyloid fibril formation.
Atomic force microscopy imaging and substrate preparation
Atomic force microscopy (AFM) images were collected on a Multimode 8 AFM fitted with the Nanoscope V controller (Bruker Co., USA). Images were acquired in ScanAsyst mode using silicon tips. Samples were absorbed on freshly cleaved mica and then rinsed with nanopure water and dried with compressed air. Images were analyzed using Scanning Probe Image Processor (SPIP) software (version 6.5.2, Image Metrology A/S, Lyngby, Denmark) or NanoScope Analysis 1.5 software (Bruker Co., USA).
For imaging sPMCA products, rPrP-res RNA or rPrP-res RNA-low was treated with Benzonase (200 U/mL, 1 mM MgCl2) plus α-amylase (Sigma, 5 units/mL) at 37˚C overnight, followed by PK digestion (25 μg/mL) at 37˚C for 30 minutes. The treated samples were centrifuged at 100,000 x g for 1 h at 4˚C and the pellets were washed once in 10 mM Potassium Phosphate buffer (pH 7.4). The control sample, containing all the cofactors but no rPrP, went through the same treatments except the PK-digestion. The final pellets were resuspended in appropriate volumes of ddH 2 O for imaging. For imaging rPrP amyloid fibrils, samples were centrifuged at 100,000 x g for 1 h at 4˚C. The pellets were washed twice with ddH 2 O and resuspended in appropriate volumes of ddH 2 O for imaging.
RT-QuIC
Protein purification. The Bank Vole recombinant prion protein (rPrP Sen ) (residues 23 to 230; Methionine at residue 109; accession no. AF367624) was purified as previously described [53] . The vectors were transformed into Rosetta (DE3) Escherichia coli and grown in Luria broth medium with the addition of kanamycin and chloramphenicol. The expression of the protein was induced using the autoinduction system [54, 55] . Inclusion bodies containing the protein were denatured and the protein was isolated using Ni-nitrilotriacetic acid (NTA) superflow resin (Qiagen) with an Ä KTA fast protein liquid chromatographer (GE Healthcare Life Sciences). Refolding of the protein was done on the column by means of a guanidine HCl reduction gradient. Elution was done with an imidazole gradient as described. Following elution, the protein was extensively dialyzed into 10 mM sodium phosphate buffer (pH 5.8), filtered (0.22-μm syringe filter (Fisher)) and stored at -80˚C in 1mL aliquots. The protein concentration was determined by absorbance at 280 nm.
Brain homogenate and PMCA product dilution for RT-QuIC. Brain homogenates (BH; 10% w/v) were prepared as previously described [37] and stored at -80˚C. For RT-QuIC analysis, BHs or PMCA products were serially diluted in 0.1% SDS (sodium dodecyl sulfate, Sigma)/ N2 (Gibco)/PBS as previously reported [36] with the last dilutions prepared to a final concentration of 0.05% SDS/N2/PBS.
RT-QuIC assay protocol. RT-QuIC analysis was performed as previously reported [37] . The reaction mix included 10 mM phosphate buffer (pH 7.4), 300 mM NaCl, 0.1 mg/ml rPrP, 10 μM Thioflavin T (ThT), 1 mM ethylenediaminetetraacetic acid tetrasodium salt (EDTA), and 0.001% SDS. Aliquots of the reaction mix (98 μL) were loaded into each well of a black 96-well plate with a clear bottom (Nunc). Reactions were seeded with 2 μL of indicated BH or PMCA product dilutions. Following sealing with a plate sealer film (Nalgene Nunc International), the plate was incubated at 42˚C in a BMG FLUOstar Omega plate reader with cycles of 1 min shaking (700 rpm double orbital) and 1 min rest. ThT fluorescence measurements (450 +/-10 nm excitation and 480 +/-10 nm emission; bottom read) were taken every 45 min.
To compensate for minor differences in baselines between fluorescent plate readers and across several experiments, the data was normalized to a percentage of the maximal fluorescence response (260,000 rfu) of the plate readers following subtraction of the baseline, as described [33] . ThT fluorescence was plotted versus reaction time (hours). The reactions were classified as RT-QuIC positive base on criteria similar to those previously described for RT-QuIC analyses of brain specimens [33, 37] .
Immunoblotting of proteinase K (PK) digested RT-QuIC products. The RT-QuIC reaction conversion products were collected from the wells by extensive and vigorous scraping followed by pipetting. The samples were treated with 10 μg/ml Proteinase K (PK) for 1 hour at 37˚C with 400 rpm continuous orbital shaking. Equal volumes of PK-treated reactions were run on 12% Bis-Tris NuPAGE gels (Invitrogen). The proteins were transferred to an Immobilon P membrane (Millipore) using the iBlot Gel Transfer System (Invitrogen). The membranes were incubated with R20 primary antiserum (hamster epitope: residues 218-231) [56] diluted 1:15,000, followed by goat-anti-rabbit secondary antibody dilutes 1:5000, and visualized with the Attophos AP fluorescent substrate system (Promega) according to the manufacturer's recommendations.
Statistical analysis
Means are presented with their standard deviations and compared by one-way analysis of variance (ANOVA) followed by Tukey's multiple comparisons test, two-way ANOVA analyses followed by Tukey's multiple comparisons test, or by two-tailed unpaired multiple t test with Holm-Sidak's correction. Statistical analysis was performed with GraphPad Prism 6.05. brain was included to demonstrate that the PET blot protocol is able to detect PK-resistant PrP.
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